S. Marsan

Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.

J. Bruneau, D. Jutras-Aswad, B. Foll, 2022, Drug and alcohol dependence.

Trauma-informed Approaches to Substance Use Interventions with Indigenous Peoples: A Scoping Review

J. Burack, E. Toombs, C. Mushquash, 2021, Journal of psychoactive drugs.

Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.

J. Rehm, E. Wood, B. Le Foll, 2023, Journal of substance use and addiction treatment.

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial

B. Le Foll, D. Jutras-Aswad, M. Socías, 2022, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada

K. Venner, Nancy Worth, C. Mushquash, 2020, Journal of Substance Abuse Treatment.